Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

William Blair Initiates Coverage On ARS Pharmaceuticals with Outperform Rating

William Blair analyst Tim Lugo initiates coverage on ARS Pharmaceuticals (NASDAQ:SPRY) with a Outperform rating.
byBenzinga Newsdesk
January 4, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

William Blair analyst Tim Lugo initiates coverage on ARS Pharmaceuticals (NASDAQ:SPRY) with a Outperform rating.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Immuron Announced US DoD Naval Medical Research Center Received feedback on IND Application for New Campylobacter ETEC Therapeutic; Said IND Does Not Contain Sufficient Information

By Charles Gross
July 26, 5:45 AM
:Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products for the prevention and treatment of gut pathogens, today announced that the US Naval Medical Research Center (NMRC) has received feedback from the US Food and Drug Administration following a review of the Investigational New Drug (IND) applica

IMRN